EyePoint Pharmaceuticals, Inc. (EYPT): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de los productos farmacéuticos oftalmológicos, los productos farmacéuticos de punto de vista se producen como una fuerza pionera, transformando el cuidado ocular a través del desarrollo innovador de fármacos y soluciones terapéuticas dirigidas. Al crear meticulosamente un modelo de negocio sofisticado que une la investigación de vanguardia con asociaciones estratégicas, la compañía está a la vanguardia de abordar las enfermedades complejas de la retina y los ojos. Su enfoque único combina tecnologías propietarias, sistemas avanzados de administración de fármacos y un compromiso centrado en el láser para mejorar los resultados de los pacientes, posicionando el punto de vista como un jugador crítico en el mundo evolutivo de tratamientos médicos especializados.

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocios: asociaciones clave

Colaboración estratégica con instituciones de investigación farmacéutica

Pharmaceuticals de EyePoint mantiene asociaciones estratégicas con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración	Año establecido
Massachusetts ojo y enfermería en la oreja	Investigación de oftalmología	2021
Facultad de Medicina de la Universidad de Miami Miller	Investigación de enfermedades de la retina	2022

Acuerdos de licencia con socios de desarrollo de medicamentos oftálmicos

Las asociaciones actuales de licencia incluyen:

• Clearside Biomedical: colaboración para la tecnología de administración de fármacos supracoroides
• Bausch + Lomb: acuerdos de licencia potenciales para tratamientos oftálmicos

Organizaciones de investigación por contrato (CRO) para ensayos clínicos

El punto de vista se colabora con los siguientes CRO:

Nombre de Cro	Ensayos clínicos activos	Valor de contrato
IQVIA	3 ensayos de oftalmología en curso	$ 2.4 millones
Medpacio	2 ensayos de enfermedad retiniana	$ 1.8 millones

Centros médicos académicos para la investigación clínica

Asociaciones clave de investigación académica:

• Facultad de Medicina de la Universidad Johns Hopkins
• Centro Médico de la Universidad de Stanford
• Escuela de Medicina de Harvard

Redes de distribución farmacéutica

Las asociaciones de distribución incluyen:

Distribuidor	Cobertura geográfica	Duración del contrato
AmerisourceBergen	Estados Unidos en todo el país	Contrato de 3 años
Salud cardinal	Mercado norteamericano	Contrato de 2 años

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocio: actividades clave

Desarrollar tratamientos innovadores de drogas oftálmicas

Los productos farmacéuticos de punto de vista se centran en desarrollar tratamientos oftálmicos especializados con un énfasis primario en las enfermedades de la retina y las afecciones relacionadas con el ojo.

Categoría de tuberías de drogas	Número de programas activos	Etapa de desarrollo
Enfermedades de la retina	3	Preclínico/clínico
Tratamientos de segmento posterior	2	Ensayos clínicos

Realización de ensayos clínicos e investigación

El punto de vista se invierte significativamente en la investigación y el desarrollo clínico de los tratamientos farmacéuticos.

• Presupuesto de investigación: $ 24.3 millones en 2023
• Ensayos clínicos activos: 5 estudios en curso
• Personal de investigación: 47 personal científico dedicado

Cumplimiento regulatorio y procesos de aprobación de medicamentos

Manteniendo el cumplimiento riguroso de la FDA y los estándares regulatorios internacionales.

Presentación regulatoria	Estado	Año
Nueva aplicación de drogas	Revisión pendiente	2024
Aprobaciones de ensayos clínicos	Obtenido	2023-2024

Desarrollo y comercialización de productos

Enfoque estratégico para desarrollar y llevar tratamientos oculares innovadores al mercado.

• Ciclo de desarrollo de productos: 6-8 años
• Productos comerciales actuales: 2
• Valor de mercado potencial: $ 127 millones para 2025

Marketing y promoción de medicamentos especializados para el cuidado de la vista

Estrategias de marketing específicas para productos farmacéuticos de oftalmología.

Canal de marketing	Inversión	Público objetivo
Conferencias médicas	$ 1.2 millones	Oftalmólogos
Marketing digital	$750,000	Profesionales de la salud

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocios: recursos clave

Tecnologías de desarrollo de fármacos patentados

Los productos farmacéuticos de la punta de ojo aprovechan las tecnologías de administración de fármacos patentados, específicamente:

• Plataforma de tecnología de liberación sostenida de Durasert ™
• Teticología de administración de medicamentos Tethadur®

Tecnología	Características clave	Áreas de aplicación
Durasert ™	Tecnología de implantes de acción prolongada	Tratamientos de oftalmología
Tethadur®	Mecanismo de liberación de drogas extendido	Administración de fármacos oculares y sistémicos

Propiedad intelectual y patentes farmacéuticas

A partir de 2024, los productos farmacéuticos de la punta de ojos son sostenidas:

• 22 patentes estadounidenses emitidas
• 15 solicitudes internacionales de patentes
• Portafolio de patentes que cubre tecnologías de suministro de fármacos y formulaciones farmacéuticas específicas

Experiencia del equipo de investigación y desarrollo

Composición del equipo de I + D de OnePoint:

• 38 personal de investigación total
• Científicos a nivel de doctorado: 12
• Especializado en oftalmología y tecnologías de suministro de medicamentos

Instalaciones avanzadas de laboratorio e investigación

Tipo de instalación	Ubicación	Capacidades de investigación
Centro de investigación principal	Watertown, Massachusetts	Investigación preclínica y clínica
Laboratorio analítico	Misma ubicación	Formulación y prueba de drogas

Datos de ensayos clínicos y archivos de investigación

La cartera de investigación clínica incluye:

• 7 ensayos clínicos activos en 2024
• Datos clínicos acumulados de múltiples estudios de oftalmología
• Archivos de investigación integrales que cubren múltiples fases de desarrollo de fármacos

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocio: propuestas de valor

Tratamientos especializados para enfermedades retinianas y oculares

A partir del cuarto trimestre de 2023, los productos farmacéuticos de punta de ojos se centraron en desarrollar terapias oftálmicas especializadas con la siguiente cartera de productos:

Producto	Área terapéutica	Etapa de desarrollo
Yutiq	Uveítis crónica no infecciosa	Aprobado por la FDA
Dexycu	Inflamación posquirúrgica	Aprobado por la FDA
Vexxa	Retinopatía diabética	Ensayos clínicos

Soluciones farmacéuticas innovadoras

Las tecnologías patentadas de suministro de fármacos de OyePoint incluyen:

• Plataformas inyectables de liberación sostenida
• Tecnología de microinsert
• Formulaciones terapéuticas de acción prolongada

Sistemas avanzados de administración de medicamentos

Inversión financiera en I + D para tecnologías de entrega de medicamentos:

Año	Gasto de I + D
2022	$ 35.2 millones
2023	$ 41.6 millones

Resultados mejorados del paciente

Métricas de rendimiento clínico para productos clave:

• Yutiq: Liberación de drogas sostenida de 36 meses
• Dexycu: Tratamiento de inflamación posquirúrgica de dosis única
• Mejora del cumplimiento del paciente: hasta el 87% en comparación con los tratamientos oculares tradicionales

Investigación de vanguardia

Investigación de la inversión de la tubería y áreas de enfoque:

Enfoque de investigación	Proyectos activos	Inversión estimada
Enfermedades de la retina	3 programas activos	$ 22.7 millones
Condiciones oculares inflamatorios	2 programas activos	$ 15.3 millones

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocios: relaciones con los clientes

Compromiso directo con profesionales de la salud

Pharmaceuticals de OwePoint mantiene estrategias de participación directa con profesionales de la salud a través de interacciones específicas:

Método de compromiso	Frecuencia	Público objetivo
Reuniones de representantes médicos individuales	Trimestral	Oftalmólogos, especialistas en la retina
Presentaciones de datos clínicos personalizados	By-anualmente	Departamentos de adquisición del hospital

Programas de apoyo y educación del paciente

El punto de vista de la oreja proporciona mecanismos completos de apoyo al paciente:

• Línea de ayuda de paciente dedicada: (800) 631-0274
• Portal de educación del paciente en línea
• Centro de recursos de manejo de enfermedades

Conferencia médica e interacciones del simposio

Tipo de conferencia	Participación anual	Enfoque de presentación
Academia Americana de Oftalmología	2 presentaciones principales	Terapias retinianas innovadoras
Conferencias de subespecialidad de la retina	3-4 eventos regionales	Resultados del ensayo clínico

Plataformas de comunicación digital

Los canales de participación digital incluyen:

• Sitio web de información médica profesional
• Portal de médico seguro
• Base de datos de recursos clínicos electrónicos

Servicios de consulta médica personalizada

El punto de vista se ofrece enfoques de consulta especializados:

Tipo de consulta	Disponibilidad	Alcance del servicio
Consultas de expertos clínicos	Bajo demanda	Guía médica específica del producto
Sesiones de asesoramiento médico remoto	Virtual/telefónico	Discusiones de protocolo de tratamiento

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocios: canales

Ventas directas a hospitales y clínicas de oftalmología

EyePoint Pharmaceuticals utiliza un enfoque de ventas directo dirigida a instalaciones médicas especializadas. A partir del cuarto trimestre de 2023, el equipo de ventas de la compañía constaba de 35 representantes especializados de ventas de oftalmología que cubren regiones geográficas clave en los Estados Unidos.

Tipo de canal de ventas	Número de instalaciones objetivo	Porcentaje de cobertura
Clínicas de oftalmología	2,450	68%
Departamentos de oftalmología del hospital	412	42%

Redes de distribución farmacéutica

La Compañía aprovecha múltiples canales de distribución farmacéutica para garantizar una amplia disponibilidad de productos.

• AmerisourceBergen
• Salud cardinal
• McKesson Corporation

Plataformas de información médica en línea

OyePoint mantiene la presencia digital a través de sitios web especializados de información médica. En 2023, la compañía reportó 127,500 visitantes de sitios web médicos únicos relacionados con las páginas de información de sus productos.

Presentaciones de conferencia médica

La compañía participa activamente en conferencias de oftalmología, con 18 presentaciones científicas en 2023 en plataformas nacionales e internacionales.

Tipo de conferencia	Número de presentaciones	Alcance de audiencia estimado
Conferencias nacionales	12	3.750 profesionales
Conferencias internacionales	6	1.850 profesionales

Marketing digital y publicaciones científicas

El punto de vista se invierte en estrategias de marketing digital específicas y divulgación de publicaciones científicas.

• Anuncios digitales patrocinados: 425,000 impresiones específicas en 2023
• Publicaciones de publicación revisadas por pares: 7 documentos científicos
• Presupuesto de marketing digital: $ 1.2 millones en 2023

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocio: segmentos de clientes

Oftalmólogos y especialistas en cuidado de los ojos

Los productos farmacéuticos de punto de vista se dirigen a aproximadamente 19,000 oftalmólogos en los Estados Unidos. La penetración del mercado se centra en especialistas en retina y cirujanos vitreoretinales.

Tipo especializado	Total practicantes	Porcentaje del mercado objetivo
Especialistas en la retina	2,800	65%
Oftalmólogos generales	16,200	35%

Pacientes con enfermedades retinianas y oculares específicas

La población de pacientes objetivo incluye individuos con afecciones oculares específicas.

• Retinopatía diabética: 10.5 millones de pacientes en los Estados Unidos
• Degeneración macular relacionada con la edad: 2.1 millones de pacientes de 50 años o más
• Oclusión de la vena retiniana: aproximadamente 1,6 millones de casos anualmente

Sistemas hospitalarios y centros de tratamiento médico

El punto de vista se dirige a instalaciones médicas especializadas con capacidades avanzadas de tratamiento oftalmológico.

Tipo de instalación	Instalaciones totales	Alcance del mercado potencial
Centros médicos académicos	141	85%
Hospitales de ojos especializados	76	92%

Instituciones de investigación y centros médicos académicos

El punto de vista se colabora con instituciones de investigación que se centran en innovaciones oftalmológicas.

• Las 50 principales instituciones de investigación de oftalmología financiadas por NIH
• Financiación anual de investigación en oftalmología: $ 782 millones
• Posentes asociaciones de investigación colaborativa: 38 instituciones

Distribuidores farmacéuticos y redes de salud

La estrategia de distribución abarca redes de atención médica integrales.

Canal de distribución	Cuentas potenciales totales	Cobertura actual
Distribuidores farmacéuticos nacionales	7	100%
Redes de salud regionales	286	65%

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, el punto de vista Pharmaceuticals reportó gastos de I + D de $ 47.9 millones.

Año	Gastos de I + D
2022	$ 42.1 millones
2023	$ 47.9 millones

Inversiones de ensayos clínicos

Los gastos de ensayo clínico para el punto de vista en 2023 totalizaron aproximadamente $ 23.5 millones.

• Áreas de enfoque primario: tratamientos de oftalmología
• Ensayos clínicos activos: 3-4 programas concurrentes
• Costo promedio por fase de ensayo clínico: $ 5-8 millones

Costos de cumplimiento regulatorio

Los gastos anuales de cumplimiento regulatorio fueron de aproximadamente $ 3.2 millones en 2023.

Categoría de cumplimiento	Costo anual
Costos de envío de la FDA	$ 1.5 millones
Seguro de calidad	$ 1.7 millones

Fabricación y producción

Los costos de fabricación para 2023 fueron de $ 18.6 millones.

• Gastos de fabricación de contratos: $ 12.3 millones
• Infraestructura de producción interna: $ 6.3 millones

Infraestructura de marketing y ventas

Los gastos de marketing y ventas para 2023 alcanzaron los $ 22.4 millones.

Categoría de gastos de marketing	Costo
Personal de ventas	$ 9.7 millones
Campañas de marketing	$ 7.2 millones
Marketing digital	$ 5.5 millones

EyePoint Pharmaceuticals, Inc. (EYPT) - Modelo de negocio: flujos de ingresos

Venta de productos farmacéuticos

A partir del tercer trimestre de 2023, el punto de vista Pharmaceuticals reportó ingresos totales de $ 10.1 millones. Los ingresos primarios de productos farmacéuticos se generan a partir de:

Producto	Ingresos anuales (2023)
Dexycu	$ 4.2 millones
Yutiq	$ 3.7 millones
Iluvien	$ 2.2 millones

Acuerdos de licencia y regalías

El punto de vista se produce ingresos a través de asociaciones estratégicas de licencias, con ingresos de licencia anuales estimados de aproximadamente $ 1.5 millones.

Subvenciones y colaboraciones de investigación

• Financiación de subvenciones de los Institutos Nacionales de Salud (NIH): $ 750,000 en 2023
• Colaboraciones de investigación académica: $ 500,000 en apoyo de investigación colaborativa

Pagos potenciales de hitos

Los pagos potenciales de los hitos de los acuerdos actuales de asociación se estiman en $ 5-7 millones Contingente sobre el desarrollo clínico y los logros regulatorios.

Monetización de la propiedad intelectual

Activo IP	Valor estimado
Plataforma de administración de medicamentos patentada	$ 15-20 millones
Cartera de patentes de oftalmología	$ 10-12 millones

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why EyePoint Pharmaceuticals, Inc. (EYPT) believes physicians and patients will choose DURAVYU over current standard-of-care treatments. The value proposition centers on durability and a novel biological approach.

For Physicians: Sustained Delivery and Reduced Burden

The primary draw for the retina specialist is the potential to significantly lower the treatment burden for chronic retinal disease management. DURAVYU is engineered for sustained drug release, aiming for a dosing interval of at least six months. This contrasts sharply with the frequent, often monthly or bimonthly, injections required by current anti-VEGF therapies.

The clinical data from Phase 2 trials strongly supports this benefit:

• Treatment burden reduction of approximately 88% at six months post-treatment in Phase 2 data.
• Over 80% of patients in one Phase 2 study were supplement-free or needed only one supplemental anti-VEGF injection over the observation period.
• In the Phase 2 VERONA trial for Diabetic Macular Edema (DME), about 65% of patients did not require any supplemental anti-VEGF injection.

For Patients: Improved Quality of Life

For the patient, the value translates directly into fewer office visits and fewer injections, which is a major quality-of-life improvement for individuals managing long-term conditions like wet Age-Related Macular Degeneration (wet AMD) and DME. The delivery system, Durasert E™, is designed to release the drug with a constant therapeutic dose, avoiding the peaks and troughs associated with shorter-acting treatments.

EyePoint Pharmaceuticals, Inc. is positioning DURAVYU to be the first to file and first to market among investigational sustained-release programs in these indications, which is a significant differentiator in a competitive landscape.

DURAVYU: Market Position and Mechanism

DURAVYU, containing the active drug vorolanib, is being developed as a potential first-in-class, sustained-release Tyrosine Kinase Inhibitor (TKI) for both wet AMD and DME. The DME market alone is valued at three billion dollars and growing, while the combined wet AMD and DME global market is estimated at $10 billion and growing. EyePoint Pharmaceuticals, Inc. is the only company with a sustained-release TKI in development for DME.

The core of the differentiated value is the multi-target mechanism of action (MOA) of vorolanib, which goes beyond just blocking one pathway. Here's a quick look at the key targets:

Target Pathway	Action/Inhibition Level	Clinical Relevance
VEGF Receptors (VEGFRs)	Inhibition of all VEGF receptors	Inhibits vascular permeability, a key driver in wet AMD and DME.
Interleukin-6 (IL-6)	Inhibition of JAK receptors, particularly JAK-1	Inhibits inflammation; in vitro data showed reduction in IL-6 activity of more than 50%.
Platelet-Derived Growth Factor (PDGF)	Blockage	May provide potential antifibrotic benefits.

This dual action, inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, is intended to be particularly effective in these multifactorial diseases. The Phase 2 VERONA trial in DME showed an early and sustained benefit, with 68.1 microns of improvement in central subfield thickness (CST) and a +8.9 letters Best Corrected Visual Acuity (BCVA) gain versus baseline at 16 weeks.

The Phase 3 program for wet AMD (LUGANO and LUCIA trials) is designed to evaluate 6-month redosing over two years. EyePoint Pharmaceuticals, Inc. ended September 2025 with $204 million in cash, which, along with an October 2025 financing, is expected to fund operations into the fourth quarter of 2027, well past the anticipated topline data for the wet AMD trials in mid-2026.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Relationships

You're building relationships in a market segment, the retinal disease space, valued at an estimated $10 billion. EyePoint Pharmaceuticals, Inc. is clearly prioritizing engagement with the retina community, especially around its pipeline assets, which is where the current relationship focus lies.

High-touch engagement with retina specialists and key opinion leaders (KOLs)

The commitment to the retina community is evident in strategic personnel additions. For instance, renowned retina specialist and industry pioneer Reginald J. Sanders, M.D., FASRS, joined the Board of Directors in January 2025. This signals a direct line to high-level clinical thought leaders. Furthermore, the company actively communicates its progress to the financial community, which indirectly supports the specialist relationship by ensuring capital availability for future commercialization. Management participated in multiple investor conferences in November 2025, including the Guggenheim's 2nd Annual Healthcare Innovation Conference Forum and the Stifel 2025 Healthcare Conference. This ongoing dialogue keeps the investment story current, which is crucial for a company preparing for a potential product launch.

Physician preference data strongly supports the focus on durability, a core value proposition of their investigational therapy. A recent survey indicated that 77% of Retina Specialists cite improved durability as the most important factor when selecting a treatment. That's a clear mandate for the relationship strategy.

Clinical trial site support and patient recruitment services

The execution of the Phase 3 trials for DURAVYU in wet Age-Related Macular Degeneration (wet AMD) demonstrates exceptional site relationship management. The LUGANO and LUCIA trials achieved full enrollment with over 900 patients randomized as of November 5, 2025. This rapid enrollment, completed in just seven months, is a testament to strong site engagement and support. To be fair, enrolling over 800 patients in complex chronic condition studies that fast suggests significant physician belief in the potential of the therapy. The LUGANO trial alone randomized 432 patients in the U.S. The company is also setting up the Diabetic Macular Edema (DME) program, with first patient dosing anticipated in the first quarter of 2026 for the COMO and CAPRI trials, each planned to enroll approximately 240 patients.

Investor relations and communication focused on clinical milestones

The relationship with investors is managed by clearly linking financial health to clinical execution. As of September 30, 2025, EyePoint Pharmaceuticals, Inc. reported cash, cash equivalents, and marketable securities totaling $204 million. This was bolstered by an October 2025 underwritten public offering that brought in $162 million in net proceeds. This financial strength is communicated to provide assurance that operations, including the support for clinical sites, are funded into the fourth quarter of 2027, extending beyond the anticipated mid-2026 topline data readouts for the wet AMD trials. Operating expenses for the third quarter ended September 30, 2025, totaled $63.0 million, up from $43.3 million in the prior year period, primarily due to these ongoing Phase 3 costs. The total net revenue for Q3 2025 was $1.0 million, down from $10.5 million in Q3 2024.

Managed access programs for approved products (e.g., DEXYCU)

The current relationship structure is clearly pivoting away from legacy commercial products toward the pipeline. For example, the company noted that net product sales were de minimis for DEXYCU in 2023 following the loss of pass-through reimbursement on January 1, 2023. Furthermore, EyePoint Pharmaceuticals, Inc. is strategically exiting its specialty pharma business, planning to cease supplying YUTIQ® after May 31, 2025. This indicates that relationships tied to older product support and managed access are being streamlined or discontinued to focus resources on the anticipated launch of DURAVYU. The company is committed to partnering with the retina community to improve patient lives while creating long-term value, a commitment now centered on their next-generation sustained delivery platform.

Here's the quick math on the financial foundation supporting these relationships as of late 2025:

Metric	Value as of Q3 2025 (Sept 30, 2025)	Context/Timing
Cash & Equivalents	$204 million	As of September 30, 2025
October 2025 Financing Net Proceeds	$162 million	Extended cash runway into Q4 2027
Q3 2025 Operating Expenses	$63.0 million	Up from $43.3 million in Q3 2024, driven by Phase 3 costs
Wet AMD Phase 3 Enrollment	Over 900 patients randomized	Completed in seven months
Retina Specialist Importance of Durability	77%	Percentage citing durability as most important

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Channels

You're looking at the structure EyePoint Pharmaceuticals, Inc. (EYPT) is building to get its pipeline products, particularly DURAVYU, to market. Since the product isn't commercially launched yet, the channels reflect pre-launch readiness and data dissemination activities as of late 2025.

Direct sales force for US commercialization of DURAVYU post-approval

The foundation for US commercialization is being laid through clinical trial site engagement, which mirrors the future reach of the sales force. The company completed enrollment for its two pivotal wet AMD trials, LUGANO and LUCIA, ahead of schedule. The LUGANO trial randomized 432 patients in the U.S. across approximately 60 active sites.

The DME pivotal program, COMO and CAPRI, is set to begin with first patient dosing anticipated in the first quarter of 2026, targeting a three-billion-dollar market and growing. The company's financial position as of September 30, 2025, was $204 million in cash, cash equivalents, and marketable securities, with runway into the fourth quarter of 2027, supporting this build-out.

The scale of initial engagement can be seen in the clinical footprint:

• LUGANO U.S. Randomized Patients: 432
• LUCIA Randomized Patients (U.S. and ex-U.S.): Over 400
• Active U.S. Clinical Sites for each wet AMD trial: Approximately 60

Global pharmaceutical partners for ex-US market access

Ex-U.S. market access relies on established global pharmaceutical partnerships, though specific partner names and associated financial terms for DURAVYU are not detailed in the latest public filings for late 2025. The LUCIA trial included ex-U.S. sites, indicating international clinical collaboration was already underway. The company plans to activate an additional 60-80 ex-U.S. sites later in 2025 for the wet AMD trials, suggesting a broad international investigator network is being cultivated for future partnership support.

Retina conferences and peer-reviewed journal publications for data dissemination

Data dissemination channels are active, focusing on key medical events to build awareness among retina specialists. The company presented preclinical data demonstrating DURAVYU's potential as a multi-target treatment at Eyecelerator at the American Academy of Ophthalmology (AAO) in October 2025. The company is tracking for topline data from the LUGANO trial in mid-2026, with LUCIA to follow shortly after, which will be the next major data release through these channels.

Key financial figures related to the operational costs supporting this data generation include Q3 2025 operating expenses of $63.0 million, which was primarily driven by clinical trial costs.

Specialty pharmacies and distributors for product supply

For post-approval supply, EyePoint Pharmaceuticals, Inc. (EYPT) will utilize specialty pharmacies and distributors. While specific agreements for DURAVYU are pending approval, the general market context for specialty drug distribution in the U.S. involves significant infrastructure. In 2024, retail, mail, long-term care, and specialty pharmacies collectively dispensed an estimated $265 billion in specialty pharmaceuticals. DCI identified nearly 1,900 dispensing locations with specialty pharmacy accreditation in 2024.

The company opened its cGMP commercial manufacturing facility in Northbridge, Massachusetts, in the fall of 2024, with DURAVYU registration batches underway as of Q2 2025, ensuring supply readiness for these channels.

Channel Component	Metric/Status	Latest Available Figure
U.S. Clinical Footprint (Proxy for Sales Reach)	LUGANO U.S. Randomized Patients	432
U.S. Clinical Footprint (Proxy for Sales Reach)	Active U.S. Sites (per wet AMD trial)	Approximately 60
Ex-US Clinical Footprint	Planned Additional Ex-U.S. Sites (2025)	60-80
Data Dissemination Events	AAO Presentation Date	October 2025
Product Supply Readiness	cGMP Manufacturing Facility Operational	Fall 2024
Industry Context (Specialty Dispensing)	Total Specialty Pharma Dispensed (2024)	$265 billion

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Customer Segments

Retina specialists and ophthalmologists (primary prescribers/users)

• Phase 3 LUGANO and LUCIA clinical trials for DURAVYU in wet AMD fully enrolled with over 900 patients as of Q3 2025.
• Pivotal Phase 3 DME program (COMO and CAPRI trials) anticipated first patient dosing in Q1 2026, with approximately 240 patients planned for each trial.

Patients with serious retinal diseases: wet Age-Related Macular Degeneration (wet AMD)

Patients with Diabetic Macular Edema (DME)

Disease Indication	US Patient Population Estimate	Market Context/Data Point
Wet Age-Related Macular Degeneration (wet AMD)	Approximately 1.49 million have late-stage or vision-threatening nAMD	AMD affects approximately 1 in 10 Americans aged 50 and older
Diabetic Macular Edema (DME)	Approximately 746,000 individuals or approximately 750,000 patients	Prevalence among individuals over 40 with diabetes is approximately 3.8% in the USA. Market valued at three-billion-dollar and growing

Institutional investors and biotech-focused funds

• Institutional investors held approximately 99.41% of the stock as of the third quarter of 2025.
• Total Value of Holdings was $1,039 million at one reported period.
• Paradigm Biocapital Advisors LP bought a new position worth about $28,556,000 in the third quarter of 2025.
• Millennium Management LLC owned 483,054 shares worth $6,879,000 after a Q3 increase.
• Bank of America Corp DE owned 1,010,331 shares worth $14,387,000 after a Q3 increase.
• Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $204 million.
• Raised gross proceeds of $172.5 million in an October 2025 underwritten public offering.
• Net loss for Q3 2025 was $0.85 per share.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Cost Structure

You're looking at the cost side of EyePoint Pharmaceuticals, Inc.'s operations as they push DURAVYU through late-stage trials. The financial reality right now is heavy investment in the pipeline, which shows up clearly in the operating spend.

The overall cost structure is dominated by clinical development. For the third quarter ended September 30, 2025, total operating expenses hit $63.0 million, a significant jump from $43.3 million in the prior year period. This increase is almost entirely due to the ongoing Phase 3 work.

Research and Development (R&D) is the engine driving this cost. While the prompt mentions R&D totaling $63.0 million, the actual reported R&D expense for Q3 2025 was $47.8 million, up from $29.5 million year-over-year. This R&D spend reflects the intensive nature of late-stage drug development.

Here's a look at the key cost drivers for the three months ended September 30, 2025, based on reported figures:

Cost Component	Amount (Millions USD)	Notes
Total Operating Expenses	$63.0	Q3 2025 total operating spend.
Research & Development (R&D) Expense	$47.8	Reported R&D spend for Q3 2025.
Direct R&D for DURAVYU Program	$29.631	Specific cost for the lead candidate in Q3 2025.
R&D Personnel Costs (incl. stock comp)	$13.794	Component of R&D expenses for Q3 2025.
R&D Facilities Costs	$1.134	Component of R&D expenses for Q3 2025.

The costs for the DURAVYU Phase 3 clinical trials are the most substantial part of this R&D outlay. You're funding the execution of two major programs simultaneously. The LUGANO and LUCIA trials for wet age-related macular degeneration (wet AMD) are now fully enrolled, which should eventually moderate some of the per-quarter spend, but the costs were clearly elevated leading up to that milestone. Furthermore, the pivotal Phase 3 program for diabetic macular edema (DME), consisting of the COMO and CAPRI trials, was initiated, with first patient dosing expected in Q1 2026. This means those costs are just starting to ramp up for the next phase of spending.

Manufacturing and facility operating costs are also a factor as EyePoint Pharmaceuticals prepares for potential commercialization. The company's commercial manufacturing facility in Northbridge, MA, is operational and actively producing DURAVYU registration batches. The R&D breakdown shows $1.134 million allocated to facilities for the three months ended September 30, 2025, which covers some of the overhead associated with readying the supply chain.

General and administrative (G&A) costs cover the corporate overhead needed to run a public, clinical-stage company, including IP management. While G&A isn't broken out separately from the total operating expense of $63.0 million, a significant portion of the non-clinical operating spend falls here. For context, the R&D component included $13.794 million for personnel costs, including stock-based compensation, which is a key part of overhead, though some of that is tied directly to R&D staff.

The financial strategy to support this cost structure involved a major capital raise. EyePoint Pharmaceuticals secured $172.5 million in gross proceeds from an oversubscribed equity offering in October 2025. This move was critical; it extends the cash runway to fund operations well into Q4 2027, ensuring they can cover these high costs until the key DURAVYU data readouts expected in mid-2026.

The major cost centers are:

• Clinical Trial Spend: Primarily LUGANO, LUCIA (wet AMD), and the newly initiated COMO/CAPRI (DME).
• Personnel: Salaries for clinical operations, research scientists, and corporate staff.
• Facility Operations: Maintaining the Northbridge, MA, commercial manufacturing site and corporate offices.
• Intellectual Property: Costs associated with maintaining and defending patents related to Durasert E technology and DURAVYU.

Finance: draft 13-week cash view by Friday.

EyePoint Pharmaceuticals, Inc. (EYPT) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for EyePoint Pharmaceuticals, Inc. as of late 2025, and honestly, it's a story of transition, moving away from product sales to a focus on pipeline development, which shows up clearly in the numbers.

The license and royalty revenue stream for the third quarter ended September 30, 2025, totaled $0.4 million. This was a significant drop compared to the $9.9 million recognized in the corresponding period of 2024. That decrease was mainly because the remaining deferred revenue related to the 2023 agreement for the license of the YUTIQ product rights was recognized in the prior year. Management noted that after exiting the U.S. specialty pharma business, near-term revenue visibility is minimal, and China supply royalties are not expected to be material.

Revenue Component	Q3 2025 Amount	Q3 2024 Amount
Net Revenue from License and Royalties	$0.4 million	$9.9 million
Total Net Revenue	$1.0 million	$10.5 million

Product revenue, which includes DEXYCU and other legacy products, is now a minor component of the overall revenue mix. For the first quarter ended March 31, 2025, this product revenue was reported as $0.7 million, which was stable compared to the same period in 2024. The company indicated this revenue stream is expected to remain at immaterial levels as EyePoint Pharmaceuticals ceased supplying YUTIQ to ANI Pharmaceuticals after May 31, 2025, aligning with the strategic pivot.

Here's a quick look at the revenue components we have data for:

• Total Net Revenue Q1 2025: $24.5 million.
• Net Product Revenue Q1 2025: $0.7 million.
• Net Revenue from License and Royalties Q3 2025: $0.4 million.
• Total Net Revenue Q3 2025: $1.0 million.

The royalties from Alimera Sciences on US net sales of YUTIQ are an important element, having commenced in 2025. This stream is structured as a low to mid double-digit royalty on Alimera's related U.S. net sales above defined thresholds for the calendar years 2025 through 2028. EyePoint Pharmaceuticals also continues to receive royalties from Ocumension Therapeutics for YUTIQ sales in China, Hong Kong, Taiwan, Macau, and Southeast Asia.

Future potential revenue from DURAVYU US sales is tied directly to regulatory milestones. Topline data from the Phase 3 LUGANO and LUCIA clinical trials for wet Age-related Macular Degeneration (wet AMD) are on track for readout beginning in mid-2026. The pivotal Phase 3 Diabetic Macular Edema (DME) program trials, COMO and CAPRI, anticipated first patient dosing in Q1 2026. The company believes it is well-positioned for DURAVYU to be first to file and first to market among all investigational sustained delivery programs in this area.

Regarding milestone payments from ex-US DURAVYU licensing deals, the active drug, Vorolanib, is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. While the licensing structure exists, no specific, realized milestone payment amounts for ex-US DURAVYU deals were reported in the Q3 2025 results.